Manya Magnus, PhD, MPH

Manya Magnus
Title:
Professor and Associate Chair, Department of Epidemiology, Milken Institute School of Public Health, The George Washington University
Office:
Floor 5
Address:
950 New Hampshire Avenue NW
Washington, District Of Columbia 20052
Phone:
202-994-3024
Email:
[email protected]
Website:
Faculty Profile

Current HIV/AIDS Research Activities:

  • The District of Columbia Clinical Trials Unit. Role: Principal Investigator/CTU Leader
  • The District of Columbia Center for AIDS Research. Role: Co-Director, Clinical and Population Sciences Core
  • HPTN 083, A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men. Role: Site Leader/IoR
  • HVTN 136/HPTN 092, A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of the monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS via intravenous infusion or via subcutaneous injections in healthy, HIV-uninfected adult participants. Role: Co-Site Leader
  • HVTN 405/HPTN 1901, Characterizing SARS-CoV-2-specific immunity in convalescent individuals. Role: Site Leader/IoR
  • STRENGTHENING ETHICAL REVIEW CAPACITY IN DEMOCRATIC REPUBLIC OF CONGO (SERC-DRC) (PI: Hyder). Role: Co-Investigator
  • CoVPN3001, Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older. Role: CTU Leader/Co-Investigator
  • HPTN 094, INTEGRA: A Vanguard Study of Integrated Strategies for Linking Persons with Opioid Use Disorder to Care and Prevention for Addiction, HIV, HCV and Primary Care. Role: CTU Leader/Co-Investigator

Completed studies:

  • HIV Prevention Trials Network, GWU HPTN Clinical Research Site (NIH). Role: CRS Leader (through 2020)
  • HPTN 085/HVTN 704, HVTN 704/HPTN 085, A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men Role: Site Leader/IoR
  • National HIV Behavioral Surveillance study (part of the Department of Epidemiology and Biostatistics/HAA Public Health/Academic Partnership)-CDC/DC DOH: Co-Investigator (Former Site PI)
  • HPTN 077, A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women (DAIDS/NIH): Study Leader, CRS Leader. Role: Site Leader/IoR
  • BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication (PI: Nixon). Role: Co-Director, Community Engagement Core
  • Structural barriers to HIV prevention service utilization among Black MSM. Role: Principal Investigator
  • Use of telemedicine to overcome barriers to care among transgender women of color. Role: Principal Investigator
  • Mucosal Immune Responses in the Reproductive Tract of Post-Menopausal Women: Impact of sexual violence and HIV status (PI: Ghosh/Greenberg). Role: Co-Investigator/Mentor
  • Advancing Pre-exposure Prophylaxis (PrEP) Delivery among Black MSM in the District of Columbia (PI: Siegel/Greenberg). Role: Co-Investigator/Mentor
  • HPTN 069, A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir disoproxil fumarate (MVC+TDF), or Tenofovir disoproxil fumarate + Emtricitabine (TDF+FTC) For Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Transmission in At-Risk Men Who Have Sex with Men and in At-Risk Women (DAIDS/NIH) Role: Site Leader/IoR
  • HPTN 073, Pre Exposure Prophylaxis (PrEP) Initiation and Adherence among Black Men who have Sex with Men (BMSM) in Three US Cities (DAIDS/NIH). Role: Site Leader/IoR
  • HPTN 061, Feasibility of a community-level, multi-component intervention for Black MSM in preparation for a Phase IIB community-level randomized trial to test the efficacy of the intervention in reducing HIV incidence among Black MSM (DAIDS/NIH). Role: Site Leader/IoR
  • HPTN 064, The Women's HIV SeroIncidence Study (ISIS) (DAIDS/NIH): Role: Co-Site Leader

Current HIV/AIDS Educational Activities

  • Course Director, Epidemiology of HIV/AIDS, GWU SPH, Department of Epidemiology
  • Course Director, Advanced Epidemiologic Methods (Spring), GWU SPH, Department of Epidemiology
  • Co-Director, MPH Program in Epidemiology

A complete list of Dr. Magnus' peer-review publications can be viewed here.